

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
WO 02/34918 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/31,  
15/63, C07K 14/245, 16/12, A61K 39/108, C12Q 1/44,  
1/68

(21) International Application Number: PCT/US01/47719

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/243,675 26 October 2000 (26.10.2000) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH  
FOUNDATION [US/US]; P.O. Box 7365, Madison, WI  
53707-7365 (US).

(72) Inventors: WELCH, Rodney, A.; 1825 Van Hise Avenue,  
Madison, WI 53705 (US). LATHEM, Wyndham, W.; 508  
West Wilson, #1, Madison, WI 53703 (US).

(74) Agents: FAHRLANDER, Jill, A. et al.; Michael Best &  
Friedrich, LLP, One South Pinckney Street, Suite 700, P.O.  
Box 1806, Madison, WI 53701-1806 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).


Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: E.COLI 0157:H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN AND METHODS OF USE

WO 02/34918 A2



(57) Abstract: Disclosed is a p0157 plasmid-specified polypeptide found in *E.coli* EDL933 and other enterohemorrhagic *E.coli* that binds to and cleaves C1-esterase inhibitor. Also disclosed are methods employing the polypeptide for diagnosing and treating colitis or hemolytic uremic syndrome, and methods of detecting potential therapeutics

-1-

E. COLI O157:H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN  
AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Application No. 60/243,675, filed October 26, 2000.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR  
DEVELOPMENT

[0002] This invention was made with United States government support awarded by  
\_\_\_\_\_.

BACKGROUND OF THE INVENTION

[0003] Enterohemorrhagic *Escherichia coli* (EHEC) serotype O157:H7 strain is a human enteric bacterial pathogen that causes diarrheal disease, hemorrhagic colitis, and hemolytic uremic syndrome (HUS). Each year in the United States, an estimated 20,000 people suffer from diarrheal disease associated with *E. coli* O157:H7 infection, which is typically contracted by ingesting contaminated foods, especially undercooked meat. Approximately 6% of infected individuals develop HUS, which can lead to renal failure and death. Young children and the elderly are particularly susceptible to developing HUS.

[0004] In general, bacterial infections are commonly treated by administering appropriate antibiotics. However, *E. coli* O157:H7 infection typically has a very rapid progression, and is consequently very difficult to treat. Often by the time the disease is diagnosed, the infected individual is severely ill and toxic proteins secreted by the bacteria may have damaged mucosal cells and entered the blood stream. Antibiotic treatment of patients infected with *E. coli* O157:H7 is generally not successful, and is now believed to be contraindicated.

[0005] *E. coli* O157:H7 bacteria are very proficient at establishing an infection; ingestion of as few as 10 live bacteria is sufficient to establish an infection. The highly

-2-

infective nature of *E. coli* O157:H7 and the devastating sequelae associated with infection by this bacteria, together with the extensive public attention given to outbreaks of hemorrhagic colitis, has generated a great deal of interest among medical professionals and the general public in developing the means for early diagnosis and treatment of the disease. The entire genome of the *E. coli* O157:H7 EDL933W (ATCC 43895) was sequenced with the expectation that valuable information concerning the organism's pathogenicity would be uncovered, which may facilitate development of methods of preventing infections, or preventing or treating hemolytic uremic syndrome in individuals infected with of the organism. The DNA sequence of *E. coli* O157:H7 was compared with that of *E. coli* K12, a non-pathogenic strain commonly used in research. The genome of *E. coli* O157:H7 exceeds that of *E. coli* K-12 by more than a million base pairs and has up to 1000 genes not found on K-12. These additional gene sequences are distributed throughout more than 250 sites in islands, with each island containing from zero to sixty genes (1).

[0006] What is needed in the art is an improved understanding of factors involved in the pathogenesis of *E. coli* O157:H7, and methods for preventing or treating hemolytic uremic syndrome in individuals infected with *E. coli* O157:H7. What is also needed in the art is an understanding of factors responsible for enteric disease that are common to pathogenic *E. coli*.

#### BRIEF SUMMARY OF THE INVENTION

[0007] The present invention provides an isolated polypeptide comprising the amino acid sequence of amino acid residues 230-630 of SEQ ID NO:2.

[0008] In another aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence having at least 70% amino acid identity to amino acid residues 24-886 of SEQ ID NO:2, the polypeptide comprising a sequence corresponding with and identical to amino acids 434-444 of SEQ ID NO:2 and having the ability to bind to and cleave C1 esterase inhibitor.

-3-

[0009] In another embodiment, the present invention provides an isolated polypeptide, the amino acid sequence of which comprises at least 17 consecutive amino acid residues of SEQ ID NO:2.

[0010] In yet another aspect, the present invention provides a genetic construct comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of amino acid residues 24-886 of SEQ ID NO:2 or a sequence complementary thereto, the polynucleotide operably linked to an expression control sequence. Additionally, the present invention is drawn to a cell comprising the genetic construct.

[0011] In another embodiment, the present invention includes an antibody that binds specifically to an antigenic determinant found on a polypeptide comprising an amino acid sequence comprising SEQ ID NO:2, preferably to an epitope in the C1 esterase inhibitor binding domain of the polypeptide.

[0012] In another aspect, the present invention provides a method of preventing or treating colitis or hemolytic uremic syndrome in a subject infected with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence substantially homologous to SEQ ID NO:2, the inhibitor protein being capable of reducing the activity of C1 esterase inhibitor, comprising administering to the subject an antibody that binds specifically to an antigenic determinant found on a polypeptide having the amino acid sequence of SEQ ID NO:2, or a chelator capable of binding divalent cations, the antibody or chelator administered in an amount effective to reduce proteolytic inactivation of C1 esterase inhibitor by the inhibitor protein.

[0013] Another aspect of the invention provides a method of preventing colitis or hemolytic uremic syndrome in a subject at risk for infection with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence substantially homologous to SEQ ID NO:2, the inhibitor protein being capable of reducing the activity of C1 esterase inhibitor, comprising administering to the subject an inactivated polypeptide comprising at least one antigenic determinant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 in an amount effective to induce an immune response.

-4-

[0014] In another aspect, the invention provides a method of preventing or treating colitis and/or hemolytic uremic syndrome in a subject infected with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence substantially homologous to SEQ ID NO:2, the protein inhibitor being capable of reducing the activity of C1 esterase inhibitor, comprising the step of administering to the subject C1 esterase inhibitor in an amount effective to reduce activation of at least one proteolytic cascade selected from the group consisting of classical complement cascade, intrinsic coagulation pathway, and kinin-forming system.

[0015] The present invention provides a method of testing a molecule for the ability to reduce proteolysis of C1 esterase inhibitor by an inhibitor protein comprising an amino acid sequence substantially homologous to amino acid residues 24 to 886 of SEQ ID NO:2, the inhibitor protein being capable of proteolyzing C1 esterase inhibitor, comprising combining the inhibitor protein, test molecule, and C1 esterase inhibitor under suitable conditions for a period of time sufficient to allow inhibitor protein-C1 esterase inhibitor interaction; and comparing the level of the C1 esterase inhibitor or C1 esterase inhibitor activity to that of a control lacking the test molecule.

#### BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0016] Fig. 1 shows the differential effect of E. coli strains containing (Fig. 1A and Fig. 1C) or lacking (Fig. 1B and Fig. 1D) the plasmid pO157 on aggregation of T cells.

[0017] Fig. 2 shows stained proteins separated by SDS/PAGE.

[0018] Fig. 3 shows that synthesis of StcE correlates with the presence of pO157.

[0019] Fig. 4 shows that C1 inhibitor in human serum is cleaved by StcE.

[0020] Fig. 5 shows cleavage of C1 inhibitor over time.

[0021] Fig. 6 shows differential cleavage of C1-INH by StcE and elastase.

[0022] Fig. 7 is an immunoblot showing a StcE-reactive band in fecal filtrates.

-5-

[0023] Fig. 8A shows that StcE E435D-His is unable to cleave C1-INH; Fig. 8B shows that StcE E435D-His is unable to bind C1-INH.

[0024] Fig. 9 shows amplification of three *stcE*-specific sequences from all *E. coli* isolates containing the pO157, and amplification of two of the three *stcE*-specific sequences.

[0025] Fig. 10 shows an immunoblot of culture supernatants probed with a polyclonal antibody to StcE.

[0026] Fig. 11 shows an immunoblot of C1-INH following incubation with culture supernatants, probed with anti-C1-INH antibody.

#### DETAILED DESCRIPTION OF THE INVENTION

[0027] Strains of the serotype O157:H7 EDL933W carry a 92 kb plasmid designated pO157. As described in the Examples below, bacterial strains containing the plasmid cause the aggregation of two cultured human CD4<sup>+</sup> T cell lines, Jurkat and MOLT-4, but not a B cell lymphoma line (Raji), or macrophage-like cell lines (U937 and HL-60). Aggregation of the cells occurs in the presence of serum, but not in the absence of serum. Strains lacking the plasmid do not cause aggregation. We employed transposon mutagenesis to identify a gene on pO157 of previously unknown function whose product is associated with the observed aggregation effect. The coding sequence and the deduced amino acid sequence of the protein it encodes are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively. The protein, designated "StcE", contains a putative cleavable N-terminal signal sequence, is secreted into the culture medium, and is a protease that cleaves C1 esterase inhibitor, a protease inhibitor that controls the activation of C1, the first component of the complement cascade.

[0028] As one of skill in the art would appreciate, a protein comprising an amino acid sequence having minor substitutions, deletions, or additions from that of SEQ ID NO:2 would be suitable in the practice of the present invention. Conservative amino acid substitutions are unlikely to perturb the protein's secondary structure and interfere with its activity. SEQ ID NO:2 includes the N-terminal signal sequence, which although

expressed, is unlikely to be found on an isolated polypeptide. The expressed StcE protein likely undergoes post translational modification that results in cleavage of the N-terminal signal peptide. It is likely that StcE isolated from culture medium in which *stcE* positive strains are grown comprises amino acid residues 24-886 of SEQ ID NO:2. As shown in the Examples below, it appears that the 5' region of the StcE gene and promoter is less highly conserved than the 3' region of the gene.

[0029] It is specifically envisioned that isolated polypeptides having less than the full length sequence of amino acid residues 24-886 of SEQ ID NO:2 will be useful in the practice of the present invention. StcE polypeptides that are truncated at the N-terminal or C-terminal regions and but have an intact metalloprotease binding domain corresponding to amino acid residues 434-444 of SEQ ID NO:2 may retain the ability to bind to and/or cleave the C1 esterase inhibitor. Binding and proteolytic activity of polypeptides can be evaluated using the methods set forth herein in the Examples, or by any suitable method. It is expected that StcE polypeptides that are truncated at the N-terminal or C-terminal regions or a polypeptide comprising an amino acid sequence comprising at least 17 consecutive amino acid residues of SEQ ID NO:2 may be used as an antigen against which antibodies specific for StcE may be raised. Preferably, the polypeptide comprises at least 25 consecutive amino acid residues of SEQ ID NO:2. More preferably still, the polypeptide comprises at least 40 consecutive amino acid residues of SEQ ID NO:2. One of ordinary skill in the art could easily obtain any of the various polypeptides comprising a portion of SEQ ID NO:2 by subcloning a sequence encoding the polypeptide into an expression vector, introducing the expression vector into a suitable host cell, culturing the cell, and isolating the expressed polypeptide using standard molecular biological techniques.

[0030] As used herein, an "inhibitor protein" is a polypeptide having substantial sequence identity with amino acid residues 24 to 886 of SEQ ID NO:2. As used herein, an inhibitor protein with substantial sequence identity to amino acid residues 24 to 886 of SEQ ID NO:2 comprises an amino acid sequence that has at least 70% amino acid identity to amino acid residues 24 to 886 of SEQ ID NO:2 and which has inhibitor protein activity. As used herein, "inhibitor protein activity" includes the ability to bind

-7-

to C1 esterase inhibitor, proteolyze C1 esterase inhibitor, and promote T cell aggregation in the presence of C1 esterase inhibitor. More preferably, an inhibitor protein of the present invention has 90% amino acid identity with amino acid residues 24-886 of SEQ ID NO:2; most preferably still, an inhibitor protein of the present invention has 95% amino acid identity with amino acid residues 24-886 of SEQ ID NO:2.

[0031] By an "isolated polypeptide" is meant a polypeptide that has been at least partially purified from contaminants and which is found other than in its natural state. For example, a isolated polypeptide could be obtained from a fecal sample by filtering the sample. One may obtain an isolated polypeptide using any partial purification of the polypeptide from the supernatant of a culture of bacterium that secrete the polypeptide, or from a bacterial cell lysate of bacteria that express but the polypeptide but do not secrete it.

[0032] In the examples below, polyclonal antibodies were raised against StcE protein in a band excised from a polyacrylamide gel. These antibodies were found to bind specifically to StcE protein. An antibody that binds specifically to an antigenic determinant is one that binds to a protein corresponding to a polypeptide comprising the amino acid sequence of amino acid residues 24-886 of SEQ ID NO:2, or to peptide fragments thereof, but does not bind significantly to other proteins. One of skill in the art will appreciate that using standard methods, one could raise monoclonal antibodies to a polypeptide comprising the amino acid sequence of amino acid residues 24-886 of SEQ ID NO:2 or peptide fragments, and that the monoclonal antibodies would also be useful in the practice of the present invention.

[0033] It is envisioned that an antibody preparation comprising at least one antibody directed against any of the antigenic determinants of the polypeptide of amino acid residue 24-886 could be used to passively immunize a person against a bacterium expressing a StcE protein. Preferably, the antibody preparation comprises an antibody that binds in the region of amino acid residues 434-444 of SEQ ID NO:2.



-8-

[0034] Because the StcE protein is a metalloprotease that requires zinc for its activity, it is envisioned that infections with bacteria expressing StcE or a related protein may be treated by delivering an agent capable of binding to a divalent cation in an amount effective in preventing or treating colitis or hemolytic uremic syndrome in a patient infected with an enterohemorrhagic pathogen expressing an inhibitor protein having substantial sequence identity to amino acid residues 24-886 of SEQ ID NO:2. Examples of suitable chelators include, without limitation, EDTA, meso-2,3-dimercaptosuccinic acid (DMSA), bathophenanthroline-disulfonic acid (BPS), and penicillamine. The amount of each agent effective to inhibit StcE activity will, of course, depend on a variety of factors, including the age, sex, and weight of the individual, for example. To treat other conditions, EDTA has been administered at a rate of 2-3 grams per person over 3 hours. DMSA, which can chelate copper, manganese, molybdenum, and zinc, as well as lead, mercury, cadmium, and arsenic, has been administered for treating heavy metal toxicity, and may be taken orally. Typical dosage protocols range from 500mg/day every other day for a minimum of 5 weeks to 10-30 mg/kg/day using a three-days-on, 11-days-off cycle for a minimum of 8 cycles. However, it is expected that shorter periods of treatment may be indicated. Penicillamine, another chelator primarily used to treat arthritis, can chelate copper, iron, and zinc. It is expected that dosages in the range of 125-750 mg/day may be effective.

[0035] It is also expected that the adverse effects that derive from the proteolytic activity of StcE inhibitor protein may be counteracted by administering to the patient C1-INH in an effective amount. To treat acute attacks of hereditary angioedema (HAE), as little as 25 U/kg has been given to patients (2). For other diseases, initial doses range vary from about 60 U/kg intravenously (i.v.) for patients with vascular leak syndrome to about 6000 U/kg i.v. for patients with severe thermal injury with septic shock. These initial doses can be followed by repeated administration of C1-INH over several days, if necessary. A regimen including an initial dose of 2000-4000 U/kg i.v., followed by additional C1-INH injections (e.g., 1000 U/kg i.v. daily for four days, and variations thereof) has been used to treat septic shock (3). C1-INH can be obtained commercially from various vendors (e.g., Cortex Biochem), or can be prepared from pooled human plasma by a variety of protocols (2) (4).

[0036] As described below in the examples, the *stcE* ORF was amplified by PCR, the PCR product comprising the *stcE* ORF was functionally inserted into an expression vector, the recombinant vector was introduced into a bacterial host, and the bacterial host was cultured under conditions suitable for expression of the StcE protein. The StcE protein was purified and characterized as described below in the examples. The above described method of expressing and isolating StcE is a preferred method of obtaining an inhibitor protein of the present invention. However, as one of ordinary skill in the art will appreciate, the protein may be isolated from any other source, including, for example, from culture medium in which bacteria harboring the pO157 plasmid are grown.

[0037] The ability of an isolated polypeptide to bind C1-INH or cleave C1-INH may be assessed using any suitable method, including those methods described in detail in the examples below.

[0038] In order to evaluate the StcE protein for possible cytotoxic effects, a variety of cell types were treated with StcE protein as described in the examples. Cells treated with StcE showed a high degree of aggregation in the presence of serum, but not in the absence of serum.

[0039] Because StcE-mediated aggregation occurred only in cells also treated with serum, the ability of StcE to bind to a specific serum protein was evaluated by Far western blotting using the StcE protein as the probe. An acidic serum protein of about 105 kDa by SDS PAGE was identified as binding to StcE. The target protein was recovered, subjected to limited digestion by an endopeptidase, and the peptide products analyzed by mass spectrometry. The protein to which the StcE protein binds was identified as C1 esterase inhibitor (C1-INH), which serves as a critical inhibitor in the proteolytic cascade involved in complement activation.

[0040] The plasma protein C1-INH is a protease inhibitor that controls the activation of C1, the first component of the complement cascade. The C1 component is made up of three subcomponents: C1q, C1r, and C1s. In the classical pathway of complement activation, C1 binds to an antigen-antibody complex or certain pathogens (e.g., HIV-1)

-10-

which causes the proteolytic autoactivation of C1r, which in turn causes the proteolytic activation of C1s. C1-INH inhibits activation of the classical pathway by binding to C1 and inactivating C1r and C1s. In addition to its role in controlling activation of the classical complement pathway, C1-INH inhibits other serine proteases involved in the intrinsic coagulation pathway and kinin-forming system (reviewed in (3)).

[0041] Treatment of serum or purified C1-INH with purified StcE results in the apparent disappearance of C1-INH, putatively as a result of specific proteolytic cleavage of C1-INH by StcE. The predicted StcE amino acid sequence comprises the sequence HEVGHNYGLGH (SEQ ID NO:3) (residues 434-444 of SEQ ID NO:2), which corresponds to the histidine rich active site of metalloproteases (5). Further evidence that StcE may be a metalloprotease is provided by the observation that proteolysis of C1-INH by StcE is reduced in the presence of EDTA or BPS, which chelate divalent metal ions (e.g.,  $Zn^{2+}$ ) required for metalloprotease activity.

[0042] Deficiencies in C1-INH can lead to a variety of diseases. For example, a hereditary deficiency in C1-INH (hereditary angiodema) is characterized by transient, recurrent attacks of intestinal cramps, vomiting and diarrhea. Hereditary defects in production of a different inhibitor of the complement cascade, Factor H, are associated with a form of hemolytic uremic syndrome (HUS) similar to that described for EHEC-mediated HUS.

[0043] Secretion of the putative protease StcE by enterohemorrhagic strains of *E. coli* EHEC may lead to proteolysis of C1-INH and reduction of C1-INH activity. Loss of C1-INH activity may result in unregulated pro-inflammatory or coagulation response that may be responsible for tissue damage in the intestine and kidney of persons infected with EHEC. It is also possible that the StcE serum-dependent cellular aggregation phenotype plays a role in the pathogenesis of HUS because one of the hallmarks of HUS is thrombocytopenia with an accumulation of a large number of platelets in renal microthrombi. The kidneys of those diagnosed with HUS also contain large amounts of deposited fibrin.

-11-

[0044] The proteolytic activity of StcE may be a common mode of pathogenesis among some diarrheagenic strains of *E. coli*. Colony blot analysis and amplification of *E. coli* DNA using oligomers specific to the pO157 version of *stcE* indicate that the *stcE* gene is common to all tested strains of *E. coli* associated with bloody colitis and HUS, but the *stcE* gene is not present in enteroinvasive, enterotoxigenic or uropathogenic strains of *E. coli*. However, some closely related strains of enteropathogenic *E. coli* contain *stcE*, which suggests that StcE may be more widely distributed among diarrheagenic *E. coli* than appreciated initially. Additionally, a search of the GenBank database has identified at least one distant homolog to StcE: a *Vibrio cholerae* protein (designated TagA) of unknown function. We can envision a method to screen for similar virulence factors produced by microbes.

[0045] StcE interacts with and cleaves the human serum protein complement C1 inhibitor in a zinc-dependent manner. Inactivation of serine protease inhibitors by this type of virulence factor may result in an unregulated pro-inflammatory and coagulation response that may be responsible for tissue damage in the intestine and kidney in patients infected with enterohemorrhagic strains of *E. coli*.

[0046] The elucidation of StcE functions may result in new targets for chemotherapeutic or immune-based prevention or treatment of EHEC diseases. Active or passive immune prophylaxis using StcE as an antigen or anti-StcE antibodies may prevent the serious sequelae associated with infections by enterohemorrhagic *E. coli*. Identification of the active site or binding sites between StcE and C1-INH may facilitate the design of drugs capable of preventing proteolysis of C1-INH and the tissue damage that results as a consequence of the loss of C1-INH activity. Administration of C1-INH to patients suffering from hereditary angiodema is a common practice (6). We envision that administration of C1-INH could be an effective therapy for patients suffering from bloody colitis, HUS or thrombotic thrombocytopenic purpura (TTP).

[0047] The following non-limiting examples are intended to be purely illustrative.

## EXAMPLES

[0048] Bacterial strains and plasmids.

[0049] A list of bacterial strains and plasmids is found in Table 1. Strains were constructed and plasmids were maintained in either *E. coli* K-12 DH1 or C600 unless otherwise noted. Recombinant DNA manipulations were performed by standard methods.

[0050] Enterohemorrhagic *Escherichia coli* strains EDL933 and EDL933cu (lacking plasmid pO157) and WAM2371 (enteropathogenic *E. coli* strain E2348/69) were provided by Dr. Alison O'Brien of the Uniformed Services University. WAM2035 (C600/pO157) was provided by Dr. Hank Lockman of the Uniformed Services University. WAM2516 (*Citrobacter rodentium* strain DBS100) was provided by Dr. David Schauer of the Massachusetts Institute of Technology. The Diarrheagenic *E. coli* (DEC) collection was a gift from Dr. Tom Whittam of the University of Pennsylvania. WAM2547 was created by transforming pLOF/Km (a gift from Dr. Victor De Lorenzo of the GBF-National Research Centre for Biotechnology, Germany) into the donor strain S17( $\lambda$ pir).

Table 1. Bacterial strains and plasmids used in this study.

Strain	Relevant phenotype or plasmid genotype	Source
C600	<i>E. coli</i> K-12	this laboratory
DH1	laboratory strain of <i>E. coli</i>	this laboratory
S17( $\lambda$ pir)	<i>E. coli</i> donor strain for conjugation	this laboratory
BL21(DE3)	<i>E. coli</i> strain for protein overexpression	Novagen
EDL933	wild-type EHEC strain	A. O'Brien
EDL933cu	EHEC strain EDL933 cured of pO157	A. O'Brien
WAM2371	EPEC strain E2348/69	A. O'Brien
WAM2516	<i>C. rodentium</i> strain DBS100	D. Schauer
DEC strains	Diarrheagenic <i>E. coli</i> collection	T. Whittam
WAM2035	C600/pO157::Tn801 (amp <sup>r</sup> )	H. Lockman
WAM2515	C600/pO157::Tn801 (amp <sup>r</sup> nal <sup>r</sup> )	this study
WAM2297	DH1/pBluescript II SK+ (amp <sup>r</sup> )	this laboratory
WAM2547	S17( $\lambda$ pir)/pLOF/Km (amp <sup>r</sup> kan <sup>r</sup> )	this study
WAM2553	C600/pWL104 (amp <sup>r</sup> kan <sup>r</sup> )	this study
WAM2562	DH1/pWL105 (amp <sup>r</sup> )	this study
WAM2572	BL21(DE3)/pWL107 (kan <sup>r</sup> )	this study
WAM2726	BL21(DE3)/pTEG1 (kan <sup>r</sup> )	this study
pLOF/Km	pGP704 carrying miniTn10kan	V. De Lorenzo
pO157	92 kb plasmid of EDL933; Tn801 at base 5413	H. Lockman
pBluescript II SK+	cloning vector	Stratagene
pET24d(+)	6xHis overexpression vector	Novagen
pWL104	pO157::miniTn10kan inserted at base 23772	this study
pWL105	pBluescript II SK+/bases 1-2798 of L7031	this study
pWL107	pET24d(+)/bases 138-2795 of L7031	this study
pTEG1	pWL107 with amino acid change E435D	this study

[0051] WAM2515 is a spontaneous nalidixic acid-resistant mutant of WAM2035.

WAM2553 was created as described below, containing a mini-Tn10kan insertion at base 23772 of pO157 (accession #AF074613). This plasmid is designated pWL104.

WAM2297 is pBluescript II SK+ in DH1. pWL105 was constructed by amplifying bases 1 to 2798 of the promoter and gene L7031/*stcE* from pO157 by polymerase chain reaction (PCR) using primer pairs 5'-CCCTCGAGTTTACGAAACAGGTGTAAAT-3' (SEQ ID NO:4) and 5'-CCTCTAGATTATTTATATACAACCCTCATT-3' (SEQ ID NO: 5); and cloning the product into the XbaI-XhoI sites of pBluescript II SK+ (Stratagene); WAM2562 is DH1 containing pWL105. pWL107 was constructed by PCR amplification of bases 138 to 2798 of the promoter and gene L7031/*stcE* from pO157 by PCR using primer pairs 5'-CCGAGCTCCGATGAAATTAAAGTAT-CTGTC-3' (SEQ ID NO:6) and 5'-CCTCGAGTTTATATACAACCCTCATTG-3'

-14-

(SEQ ID NO:7); and cloning the PCR product into the SacI-XhoI sites of pET-24d(+) (Novagen); WAM2572 is BL21(DE3) (Novagen) transformed with pWL107. The creation of WAM2726 is described below. All chemicals were purchased from Sigma (St. Louis, MO) unless stated otherwise.

### Cell lines

[0052] All cell lines were maintained in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (HyClone) and 10  $\mu$ g/ml gentamicin at 37°C with 5% CO<sub>2</sub>. The human T cell line Jurkat clone E6-1, the human promyelocytic leukemia line HL-60, and the human B cell lymphoma line Raji were obtained from ATCC, the human promyelocytic leukemia line U937 was a gift from Dr. Jon Woods of the University of Wisconsin-Madison, and the human T cell lymphoma line MOLT-4 was a gift from Dr. David Pauza of the University of Wisconsin-Madison.

### Aggregation assays.

[0053] Bacterial strains were grown overnight in Lennox L broth (with antibiotic selection when appropriate) at 37°C with agitation. Cultures were washed once with phosphate buffered saline (PBS) and resuspended in 1/10 the original culture volume in PBS. Cultures were lysed in a French Press at 20,000 lbs/in<sup>2</sup>. The resulting lysates were spun at 1000 x g to remove debris and protein concentrations were determined by the Bradford protein assay (Bio-Rad). Tissue culture cells were suspended at 10<sup>6</sup> cells/ml in RPMI 1640 and 50  $\mu$ g/ml gentamicin with 10% FBS or human serum. Fifty  $\mu$ g/ml of lysates or 50-200 ng/ml purified StcE-His (see below) were added to cells and incubated for two hours at 37°C in 5% CO<sub>2</sub>. Cells were agitated for one minute to disrupt spontaneous aggregates before visualization. Similar assays were performed in the absence of serum or with ammonium sulfate-precipitated fractions of human serum (see below); cells were washed once in RPMI 1640 and resuspended at 1 x 10<sup>6</sup> cells/ml in RPMI 1640 with 50  $\mu$ g/ml gentamicin (and human serum fractions, if indicated) before the addition of lysates or StcE-His. When indicated, ethylenediaminetetraacetic acid (EDTA) or bathophenanthroline-disulfonic acid (BPS) were added to the assays at a final concentration of 5 mM.

**Identification of *stcE***

[0054] WAM2515 was mated with WAM2547 as described (7). Transconjugants were plated onto LB plates containing 100  $\mu$ g/ml ampicillin, 50  $\mu$ g/ml kanamycin, and 50  $\mu$ g/ml nalidixic acid. Transconjugants were resuspended in 1X TES, washed once with 1X TES, and pO157/pO157::mini-Tn10kan were isolated by midi-prep (Qiagen). pO157/pO157::mini-Tn10kan were transformed into C600 and plated onto LB plates containing 100  $\mu$ g/ml ampicillin and 50  $\mu$ g/ml kanamycin. Transformants were grown overnight in Lennox L broth containing 100  $\mu$ g/ml ampicillin and 50  $\mu$ g/ml kanamycin at 37°C with agitation and lysates were screened for the ability to aggregate Jurkat cells as described above. pO157::mini-Tn10kan was isolated from clones lacking the ability to aggregate Jurkat cells and the location of the transposable element was identified by sequence analysis. One clone unable to aggregate Jurkat cells was designated WAM2553.

**Purification of recombinant StcE-His**

[0055] StcE-His was purified according to the manufacturer's instructions (Novagen). Briefly, WAM2572 was induced to produce StcE-His by the addition of IPTG to 1 mM at an O.D. of 0.5 followed by vigorous aeration at 37°C for approximately three hours. The cells were lysed in a French Press at 20,000 lbs/in<sup>2</sup> and the resulting lysate was centrifuged at 20,000 x g for 15 minutes. The insoluble pellet was resuspended in a buffer containing 5 mM imidazole and 6 M urea and the inclusion bodies were solubilized for one hour on ice. This fraction was incubated with nickel-agarose beads (Qiagen) overnight at 4°C, and the beads were washed three times with a buffer containing 60 mM imidazole and 6 M urea. Purified StcE-His was eluted from the beads with a buffer containing 300 mM imidazole and 6 M urea. Eluted StcE-His was dialyzed against three changes of PBS/20% glycerol at 4°C to remove the imidazole and urea. Protein concentration was determined by SDS-PAGE using purified  $\beta$ -galactosidase as a standard. At our request, polyclonal antibodies to purified StcE-His were prepared in rabbits by Cocalico Biologicals, Inc. Briefly, purified StcE-His was electrophoresed on an 8% polyacrylamide gel and stained with Coomassie Brilliant Blue. StcE-His was excised from the gel and injected into rabbits. Rabbits were boosted with StcE-His once a month for six months prior to exsanguinations.



**Two-dimensional gel electrophoresis**

[0056] Human serum was fractionated by ammonium sulfate precipitation, dialyzed against three changes of RPMI 1640 (Gibco) overnight at 4°C, and protein concentration was determined by Bradford assay (Bio-Rad). When indicated, protein A-sepharose was used to remove fractions of IgG. Two-dimensional electrophoresis was performed according to the method of O'Farrell (8) by Kendrick Labs, Inc. (Madison, WI) as follows: isoelectric focusing was carried out on 25 µg of 30-60% ammonium sulfate-fractionated human serum removed of IgG in glass tubes of inner diameter 2.0 mm using 2.0% pH 3.5-10 ampholines (Amersham Pharmacia Biotech) for 9600 volt-hrs. Fifty ng of an IEF internal standard, tropomyosin, was added to each sample. This protein migrates as a doublet with lower polypeptide spot of MW 33,000 and pI 5.2; an arrow on the stained gel marks its position. The enclosed tube gel pH gradient plot for this set of ampholines was determined with a surface pH electrode.

[0057] After equilibration for 10 min in buffer "0" (10% glycerol, 50 mM dithiothreitol, 2.3% SDS and 0.0625 M Tris, pH 6.8) each tube gel was sealed to the top of a stacking gel that is loaded on the top of a 8% acrylamide slab gel (0.75 mm thick). SDS slab gel electrophoresis was carried out for about 4 hrs at 12.5 mA/gel. The following proteins (Sigma) were added as molecular weight standards to a well in the agarose which sealed the tube gel to the slab gel: myosin (220 kDa), phosphorylase A (94 kDa), catalase (60 kDa), actin (43 kDa), carbonic anhydrase (29 kDa), and lysozyme (14 kDa). These standards appear as bands on the basic edge of the special silver-stained (O'Connell and Stults 1997) 8% acrylamide slab gel. The gel was dried between sheets of cellophane with the acidic edge to the left.

[0058] A similar gel was run as described above with the following differences: 250 µg of 30-60% ammonium sulfate-fractionated human serum was loaded onto the IEF gel; the second dimension was run on a 10% acrylamide slab gel and stained with Coomassie Brilliant Blue.

**Far Western blot analysis**

[0059] One hundred  $\mu$ g of 30-60% ammonium sulfate-fractionated human serum was run on a two-dimensional gel as described above but without staining. After slab gel electrophoresis the gel for blotting was transferred to transfer buffer (12.5 mM Tris, pH 8.8, 86 mM glycine, 10% methanol) and transblotted to PVDF membrane overnight at 200 mA and approximately 50 volts/gel. The PVDF membrane was blocked with 2% milk (Difco) in buffer AD (20 mM Tris, pH 7.5, 100 mM NaCl, 10% glycerol, 0.01% Tween-20) at 4°C. Two  $\mu$ g/ml purified StcE-His was added to the PVDF membrane and allowed to incubate two hours at 4°C. The membrane was washed with buffer AD and blocked with 2% milk in buffer AD. The membrane was reacted with polyclonal anti-His antibody conjugated with horse-radish peroxidase (Santa Cruz), washed with buffer AD, and developed with the LumiGlo chemiluminescence detection system (Kirkegaard & Perry Laboratories). The PVDF membrane was then stripped (62 mM Tris, pH 6.8, 2% SDS, 10 mM  $\beta$ -mercaptoethanol ( $\beta$ -ME), 30 min, 50°C), washed with buffer AD, reacted as above with only the His-HRP antibody, and developed.

**Mass spectrometry**

[0060] Of the three spots in human serum that reacted with purified StcE-His as identified by Far Western blotting, only the leftmost spot (the most acidic) of approximately 100 kDa was accessible for analysis by mass spectrometry. This spot was cut from the Coomassie Brilliant Blue-stained 10% slab gel and sent to the Protein Chemistry Core Facility at the Howard Hughes Medical Institute/Columbia University for analysis. The spot was digested with endoproteinase Lys-C and analyzed by MALDI-MS. The peptide pattern was compared against known human proteins in the SWISS-PROT database and was identified as plasma protease C1 inhibitor.

**Electrophoresis and immunoblot analyses**

[0061] Fifty  $\mu$ g whole and ammonium sulfate-precipitated human serum fractions were incubated with 500 ng purified StcE-His in 500  $\mu$ l buffer AD for two hours at room temperature and precipitated with 10% trichloroacetic acid (TCA) on ice for one hour. Precipitates were collected by centrifugation, resuspended in 1X sample buffer (2% SDS, 10% glycerol, 5%  $\beta$ -ME, 1 mM bromophenol blue, 62 mM Tris, pH 6.8), and

heated to 95-100°C for 5 min prior to electrophoresis on 8% polyacrylamide gels. Separated proteins were transferred to Hybond ECL nitrocellulose (Amersham Pharmacia Biotech) as described (9) for immunoblot analysis. Blots were blocked with 5% milk in TBST (154 mM NaCl, 20 mM Tris, pH 7.6, 0.1% Tween-20), probed with a polyclonal anti-C1 inhibitor antibody (Serotec) and then with HRP-conjugated anti-rabbit secondary antibody (Bio-Rad) before developing as described above.

[0062] Sixteen  $\mu$ g purified C1 inhibitor (Cortex Biochem) were incubated with 4.8  $\mu$ g purified StcE-His in 480  $\mu$ l buffer AD at room temperature; 30  $\mu$ l of the reaction were removed at various time points, suspended in 1X sample buffer, and heated to 95-100°C for 5 min prior to electrophoresis on 8% polyacrylamide gels. Separated proteins were transferred to nitrocellulose and reacted with anti-C1 inhibitor antibody as described above.

[0063] EDL933, EDL933cu, WAM2035, and WAM2553 were grown in Lennox L broth at 37°C overnight, centrifuged, and the culture supernatant was removed. The supernatant was precipitated with ammonium sulfate and the 0-60% fraction was resuspended at 1/100 the original culture volume and dialyzed against three changes of PBS overnight at 4°C. Twenty  $\mu$ l of the dialyzed supernatants and 30  $\mu$ g of EDL933, EDL933cu, WAM2035, and WAM2553 lysates were suspended in 1X sample buffer and heated to 95-100°C for 5 min prior to electrophoresis on 8% polyacrylamide gels. Separated proteins were transferred to Hybond ECL nitrocellulose and reacted with polyclonal anti-StcE-His antibody, followed by anti-rabbit-HRP secondary antibody.

#### **Casein proteolysis assay**

[0064] Various concentrations of StcE-His were incubated with BODIPY FL-conjugated casein for various times using the EnzChek Protease Assay Kit (Molecular Probes, Inc.) and the increase in fluorescence was measured with a fluorimeter as per the manufacturer's instructions.

#### **Lysates of *E. coli* strains carrying pOl57 induce the aggregation of transformed human T cell lines in a serum-dependent manner.**

[0065] To determine the consequence of pOl57-containing *E. coli* products on Jurkat

-19-

cells, a human T cell lymphoma line, 50 µg/ml of lysates of strains EDL933, EDL933cu, WAM2035, WAM2371, WAM2516, and C600 were applied to  $1 \times 10^6$  Jurkat cells/ml in RPMI 1640 with 10% FBS and 50 µg/ml gentamicin for two hours at 37°C in 5% CO<sub>2</sub>. After agitation for one minute to disrupt spontaneous aggregates, Jurkats were observed for the induction of aggregation. Lysates of *E. coli* strains carrying pO157 induced the aggregation of Jurkat cells while lysates of strains lacking pO157 did not (Figure 1). Lysates of other pathogenic bacteria such as enteropathogenic *E. coli* strain E2348/69 (WAM2371) and *C. rodentium* (WAM2516) capable of inducing the attaching and effacing (A/E) phenotype on intestinal epithelial cells and carrying large virulence plasmids different from pO157 were unable to induce the aggregation of Jurkat cells. To determine whether this effect was specific for Jurkat cells or could induce the aggregation of a broader host cell range,  $1 \times 10^6$  cells/ml in RPMI 1640 with 10% FBS and 50 µg/ml gentamicin of another human T cell lymphoma line, MOLT-4, two human promyelocytic leukemia cell lines, HL-60 and U937, and a human B cell lymphoma line, Raji, were treated with 50 µg/ml of EDL933 and WAM2035 lysates for two hours at 37°C in 5% CO<sub>2</sub>. pO157-containing lysates aggregated MOLT-4 cells but not HL-60, U937, or Raji cells (data not shown), indicating T cell specificity for the phenotype.

[0066] To determine the serum requirement for the induction of aggregation, 50 µg/ml of lysates of EDL933 and WAM2035 were applied to  $1 \times 10^6$  Jurkat cells/ml with 10% human serum and 50 µg/ml gentamicin for two hours at 37°C in 5% CO<sub>2</sub>. As seen with FBS, pO157-containing lysates were able to induce the aggregation of Jurkat cells in the presence of human serum. However, EDL933 and WAM2035 lysates were unable to induce the aggregation of Jurkat cells under the same conditions in the absence of serum. To further characterize the component(s) of human serum responsible for mediating Jurkat cell aggregation in the presence of StcE, we fractionated human serum by ammonium sulfate precipitation followed by dialysis in RPMI 1640. We found that 0-30% and 30-60%, but not 60-100%, ammonium sulfate-precipitated human serum was able to mediate aggregation of Jurkat cells in the presence of StcE. This indicates a factor or factors in serum is required for the aggregation of Jurkat cells when treated with lysates of pO157-containing bacteria.

**Identification and cloning of *stcE***

[0067] To localize the gene(s) on pO157 responsible for the induction of aggregation of human T cell lines, we subjected pO157 to mutagenesis using a minitransposon. Lysates of recombinant strains of *E. coli* containing pO157 mutagenized with mini-Tn10kan were tested for the ability to aggregate Jurkat cells in RPMI 1640 with 10% FBS and 50 µg/ml gentamicin. pO157::mini-Tn10kan was isolated from clones whose lysates were unable to induce the aggregation of Jurkat cells. The location of the transposon insertion in WAM2553 was determined by sequence analysis and mapped to position 23772 of pO157. The open reading frame in which the transposon inserted was designated L7031 (10) and is located immediately 5' to the general secretory apparatus on pO157. L7031/*stcE* was amplified and cloned into the XbaI-XhoI sites of pBluescript II SK+. Lysates of WAM2562 induced aggregation of Jurkat cells in the presence of serum, whereas lysates of WAM2297 (DH1 carrying pBluescript II SK+) did not, which confirms that the *stcE* gene is responsible for the phenotype.

[0068] Based on sequence analysis, we concluded that the translational start site for StcE was more likely to begin at base 138 than at base 102 (10). We therefore amplified the coding sequence for *stcE* from bases 138 to 2798 by PCR and cloned the gene in frame with a 6xHis-tag at the 3' end of the fusion in pET24d(+). We were able to overexpress and purify a recombinant his-tagged form of StcE (StcE-His) (Figure 2); this purified fusion protein was able to aggregate Jurkat cells in the presence of serum at a variety of concentrations (data not shown).

**Localization and characterization of StcE**

[0069] Using antiserum to StcE-His, we performed immunoblot analysis to examine the expression and secretion of StcE by *E. coli*. StcE is expressed by *E. coli* strains carrying pO157 at 37°C in Lennox L broth but not in strains lacking pO157 or harboring a transposon insertion in *stcE* (Figure 3). Additionally, StcE is released into the culture supernatant by strains carrying pO157 under the same growth conditions (Figure 3). As StcE contains a putative cleavable N-terminal signal sequence, it is possible that StcE is

actively released from the bacterium by the general secretory apparatus encoded on pO157.

[0070] StcE-mediated Jurkat cell aggregation is inhibited by the addition of ion chelators such as EDTA, a broad chelator of divalent cations, and BPS, a chelator specific for zinc and iron ions (data not shown). This suggests that StcE has a requirement for one or more divalent cations, most likely zinc. This is supported by the presence of an exact match to the histidine-rich consensus active site for metalloproteases, which coordinate zinc ions for activity (see discussion).

[0071] StcE-His interacts with a human serum protein(s) of approximately 105 kDa. To identify the factor(s) in human serum responsible for mediating Jurkat cell aggregation in the presence of StcE, the 30-60% ammonium sulfate-precipitated fraction of human serum was separated on a two-dimensional gel and transferred to a PVDF membrane. Using purified StcE-His as a probe, we performed Far Western blot analysis on the PVDF membrane, detecting any interactions between StcE-His and human serum proteins with an HRP-conjugated anti-His antibody. We found that StcE-His interacts with three spots of approximately 105 kDa ranging from very acidic to very basic in isoelectric point (data not shown). Probing the same membrane with only the HRP-conjugated anti-His antibody revealed that the three spots of approximately 105 kDa were specific for StcE-His (data not shown).

[0072] To identify these proteins, the 30-60% ammonium sulfate-precipitated fraction of human serum was removed of IgG and separated on another two-dimensional gel and either special silver stained or stained by Coomassie Brilliant Blue. The most acidic of the three spots (the leftmost spot) was well isolated from other proteins and excised from the Coomassie Brilliant Blue-stained gel. This spot was digested by endoproteinase Lys-C and analyzed by MALDI-MS. A comparison of the resulting peptide pattern with known human proteins in the SWISS-PROT database revealed a match with human plasma protease C1 inhibitor.

-22-

**Cleavage of C1 inhibitor by StcE-His**

[0073] To confirm the interaction between StcE and human C1 inhibitor and to test the possibility that StcE may proteolyze C1 inhibitor, whole and ammonium sulfate-precipitated fractions of human serum were mixed with StcE-His, separated by SDS-PAGE, and transferred to nitrocellulose for immunoblot analysis. Using an anti-human C1 inhibitor antibody, we detected the presence of C1 inhibitor in samples lacking StcE-His and the absence of C1 inhibitor in samples containing StcE-His (Figure 4). As predicted by Jurkat cell aggregation, the 0-30% and 30-60% ammonium sulfate-precipitated fractions of human serum were enriched for C1 inhibitor compared to the 60-100% fraction. After treatment with StcE-His, however, little to no C1 inhibitor could be detected in any of the fractions. The addition of EDTA or BPS to the mixture prevented the disappearance of C1 inhibitor from the serum samples, indicating a specific requirement for divalent cations, most likely zinc, for StcE activity (data not shown).

[0074] To confirm that the proteolysis of C1 inhibitor was a direct result of an interaction with StcE-His, we mixed purified human C1 inhibitor with StcE-His and removed aliquots of the reaction at various time points for analysis by immunoblot. Using an anti-human C1 inhibitor antibody, we detected the disappearance of a 105 kDa band corresponding to full-length C1 inhibitor and the appearance of an approximately 60 kDa cleavage product in a time-dependent manner (Figure 5).

**Examination of patient fecal filtrates for StcE**

[0075] Freshly passed stool samples from children with culture-positive *E. coli* O157:H7 (n=6), *Campylobacter jejuni* (n=2), *Shigella* B (n=2), or *Clostridium difficile* (n=2) infections were diluted 1:10 in PBS and passed through a 0.45  $\mu$ m filter. Thirty  $\mu$ l of thawed filtrate was suspended in 1X sample buffer, heated (95-100°C for 5 min) and electrophoresed on 8% polyacrylamide gels. Separated proteins were transferred to nitrocellulose and probed with a polyclonal antibody to StcE-His as described above. Twenty  $\mu$ l of the same samples was added to 1 X 10<sup>6</sup>/ml Jurkat cells in 10% FCS and

gentamicin (50  $\mu$ g/ml) for 24 hours at 37°C in 5% CO<sub>2</sub> to determine the ability of the filtrates to aggregate Jurkat cells.

#### **Construction and analyses of StcE E435D-His mutant**

[0076] The StcE E435D-His mutant was created using the PCR-based method of overlap extension (Horton *et al.* 1993). The first two PCR reactions were (i) *stcE* top strand primer 587 (5'-CCGCTCCGGTGAAGTGGAGAATA-3') (SEQ ID NO:8) with its partner mutagenic primer 592 (5'-GACCATAATTATGACCAACATCATGAC-TGA-3') (SEQ ID NO:9) and (ii) *stcE* bottom strand primer 573 (5'-CCTTATCTGCG-GAGGCTGTAGGG-3') (SEQ ID NO:10) with its partner mutagenic primer 574 (5'-TGAGTTCAGTCATGATGTTGGTCATAATTAT-3') (SEQ ID NO:11). Each reaction used 50 pM of each primer, about 100 ng of template DNA, and Deep Vent polymerase (New England Biolabs) in a 100  $\mu$ l reaction. The reactions were run in a thermocycler under appropriate conditions (11) and the resulting products were purified on a 1% agarose gel using the QIA-quick Gel Extraction Kit (Qiagen). The next PCR reaction contained 5  $\mu$ l each of the gel-purified fragments, along with the *stcE* primers 587 and 573 and Deep Vent polymerase in a 100  $\mu$ l reaction. The PCR products were gel-purified as above and cut with the restriction endonucleases *PmeI* and *BsrGI*. pWL107 was also cut with *PmeI* and *BsrGI* and the mutant PCR product was ligated into pWL107, creating pTEG1. The base substitution was confirmed by sequence analysis. pTEG1 was transformed into *E. coli* strain BL21(DE3) to create WAM2726 and StcE E435D-His was overexpressed and purified from this strain as described above. The purified protein was then analyzed for its ability to aggregate Jurkat cells as described above.

[0077] Purified C1-INH (one  $\mu$ g) was mixed with or without StcE-His (one  $\mu$ g) or StcE E435-His (one  $\mu$ g) overnight at room temperature in 500  $\mu$ l buffer AD, precipitated with TCA (to 10%), electrophoresed on an 8% polyacrylamide gel, and transferred to nitrocellulose before analysis by immunoblot with an anti-C1-INH antibody as described above.



-24-

[0078] Purified C1-INH (500 ng) and human serum (50  $\mu$ g) were electrophoresed on an 8% polyacrylamide gel in duplicate and the separated proteins were transferred to nitrocellulose for Far Western analysis. Essentially the same protocol was followed as described above with the following difference: one blot was probed with purified StcE-His (2  $\mu$ g/ml) and the other with purified StcE E435D-His (2  $\mu$ g/ml).

#### Colony blot analysis

[0079] A one kb fragment of *stcE* was PCR amplified from pO157 using the primers *stcE*5'846 (5'-GAGAATAATCGAATCACTTATGCTC-3') (SEQ ID NO:12) and *stcE*3'1773 (5'-CGGTGGAGGAACGGCTATCGA-3') (SEQ ID NO:13) under standard reaction conditions. The PCR product was purified on a 1% agarose gel using the QIA-quick Gel Extraction Kit (Qiagen) and fluorescein-labeled using the ECL random prime labeling system (Amersham Life Science). Bacterial strains from the DEC collection, EDL933, and EDL933cu were patched onto sterile Magna Lift nylon transfer membranes (Osmonics) on LB plates and grown overnight at room temperature. Colonies were lysed by placing the membranes on 3MM Whatman paper soaked in 0.5 M NaOH. Neutralization was performed by placing the membranes first on 3MM Whatman paper soaked in 1 M Tris, pH 7.5 and then on 3MM Whatman paper soaked in 0.5 M Tris, pH 7.5/1.25 M NaCl. DNA was then crosslinked using a UV stratalinker. The blots were pre-hybridized in Church buffer (0.5 M dibasic sodium phosphate, pH 7.3, 7% SDS, 1% BSA, 1 mM EDTA) at 65°C for one hour before the addition of the labeled probe. Hybridization proceeded overnight at 65°C. The membranes were then washed at 65°C in 1 X SSC/0.1% SDS for 15 minutes and then in 0.5X SSC/0.1% SDS for 15 minutes. The membranes were incubated with an anti-fluorescein labeled, HRP-conjugated antibody. The membrane was developed using the LumiGLO Chemiluminescent Substrate Kit (Kirkegaard and Perry Laboratories).

#### PCR analysis of *stcE*

[0080] Oligonucleotides were designed to amplify by PCR regions of *stcE* to cover the length of the ~2.8 kbp promoter and gene. Primers *stcE*5'1 (5'-TTTACGAAACA-GGTGTAAATATGTTATAAA-3') (SEQ ID NO:14) and *stcE*3'845 (5'-CAGTTCACCG-GAGCGGAACCA-3') (SEQ ID NO:15) covered the first third,

-25-

*stcE5'*846 and *stcE3'*1773 covered the middle third, and *stcE5'*1774 (5'-GCTTCAGC-AAGTGAATGCAGATAC-3') (SEQ ID NO:16) and *stcE3'*2798 (5'-TTATTTAT-ATACAACCCTCATTGACCTAGG-3') (SEQ ID NO:17) covered the final third. Genomic DNA was isolated from *E. coli* strains DEC3A-E, DEC4A-E, DEC5A-E, EDL933, and EDL933cu using the Wizard Genomic DNA Purification Kit (Promega) as per the manufacturer's instructions. PCR was performed using 20 pM of each primer, about 100 ng of template DNA, and Deep Vent polymerase (New England Biolabs) in a 100  $\mu$ l reaction. The reactions were run in a thermocycler under standard conditions. PCR products were electrophoresed on 1% agarose gels and visualized with ethidium bromide.

#### Isolation and analyses of bacterial culture supernatants

[0081] *E. coli* strains DEC3A-E, DEC4A-E, DEC5A-E, EDL933, and EDL933cu were grown in Lennox L broth at 37°C overnight. Culture supernatants were harvested by centrifugation at 4°C for 15 minutes at 10,000 x g and filtered through a 0.45 $\mu$ m filter. Supernatants were precipitated with ammonium sulfate to 75% saturation. The precipitates were centrifuged for 15 minutes at 16,000 x g at 4°C and resuspended in buffer AD. The resuspended precipitates were dialyzed against three changes of AD buffer overnight to remove residual ammonium sulfate.

[0082] Purified C1-INH (one  $\mu$ g) was mixed with 200 $\mu$ l of ammonium sulfate-precipitated culture supernatants at room temperature overnight in a total volume of 500  $\mu$ l buffer AD before precipitation with TCA (to 10%) and electrophoresis on 8% polyacrylamide gels. Separated proteins were transferred to nitrocellulose and immunoblot analysis was performed with an anti-C1-INH antibody as described above. Culture supernatants alone were separated on 8% polyacrylamide gels and transferred to nitrocellulose before immunoblot analysis was performed using an anti-StcE-His antibody as described above.

#### Specificity of StcE-His for C1-INH

[0083] To evaluate the specificity of StcE-His, potential target proteins (listed in Table 2), target protein (2  $\mu$ g) was mixed with either StcE-His (1.28  $\mu$ g) or *Pseudomonas aeruginosa* elastase (20 ng) (Calbiochem EC# 3.4.24.26) overnight at 37°C in 500  $\mu$ l

-26-

buffer AD (20 mM Tris, pH 7.5, 100 mM NaCl, 10% glycerol, 0.01% Tween-20) and precipitated with TCA (to 10%) prior to electrophoresis on 8-10% polyacrylamide gels. Proteins in the gels were then Coomassie-stained or transferred to nitrocellulose for immunoblot analysis as above.

[0084] StcE is able to cleave both purified and serum-associated C1-INH. Only C1-INH was cleaved by StcE-His; the sizes and staining intensities of all other potential substrates were the same in the presence and absence of StcE-His. In contrast, elastase degraded most of the proteins tested. Elastase treatment of C1-INH normally produces an inactive 95 kDa product (12), whereas treatment of C1-INH with StcE-His results in ~60-65 kDa C1-INH fragment(s) (Figure 6). This indicates that the StcE cleavage site of C1-INH is distinct from that used by elastase. We employed a sensitive fluorimetric assay based on the digestion of a BODIPY FL-labeled casein substrate (EnzChek, Molecular Probes) to analyze further the ability of StcE-His to act as a non-specific endoprotease. Serial two-fold dilutions of StcE-His or *P. aeruginosa* elastase were mixed with the casein substrate per the manufacturer's instructions before fluorescent measurement of casein degradation. StcE-His was unable to degrade casein even at high protein concentrations (up to 6.4  $\mu$ g/unit of volume), while elastase was able to act on casein at lower concentrations (range: 0.5 ng to 1  $\mu$ g/unit of volume) (data not shown).

Table 2. Proteolysis of substrates incubated with StcE-His or *P. aeruginosa* elastase

Substrate	StcE	Elastase
C1 inhibitor (Cortex Biochem, San Leandro, CA)	+	+
$\alpha$ 2-antiplasmin (Calbiochem, San Diego, CA)	-	+
$\alpha$ 1-antitrypsin (Sigma, St. Louis, MO)	-	+
$\alpha$ 1-antichymotrypsin (Sigma, St. Louis, MO)	-	+
antithrombin (Enzyme Research Labs, South Bend, IN)	-	+
$\alpha$ 2-macroglobulin (Calbiochem, San Diego, CA)	-	+
von Willebrand factor (gift from Dr. D. Mosher, UW-Madison)	-	N.D.
collagen IV (Rockland, Gilbertsville, PA)	-	-
fibronectin (Calbiochem, San Diego, CA)	-	+
serum albumin (New England Biolabs, Beverly, MA)	-	N.D.
IgA1 (Cortex Biochem, San Leandro, CA)	-	+
Elastin (Sigma, St. Louis, MO)	-	+
Gelatin (BioRad, Hercules, CA)	-	+

N.D. = not done

Two  $\mu$ g of the indicated protein substrates were mixed with 1.28  $\mu$ g StcE-His or 20 ng *P. aeruginosa* elastase overnight at 37°C prior to electrophoresis by SDS-PAGE and staining with Coomassie Brilliant Blue. StcE was unable to digest any of the proteins tested other than C1-INH, while *P. aeruginosa* elastase had activity against a broad range of targets.

#### Detection of StcE in feces.

[0085] The Shiga-like toxin has been identified in the feces of patients infected with *E. coli* O157:H7 (13, 14). To demonstrate that StcE is produced *in vivo* during an *E. coli* O157:H7 infection, we examined fecal filtrates collected from patients with *E. coli* O157:H7 and non-*E. coli* O157:H7-mediated diarrhea for the presence of StcE antigen and activity. Twelve fecal samples were diluted in PBS and filtered before analysis by immunoblot with polyclonal antibodies to StcE-His. A strongly reactive band with a molecular weight similar to StcE was present in the filtrate from one child infected with *E. coli* O157:H7 (Figure 7, sample 2). Because StcE is able to mediate the aggregation of T cells, we examined the ability of the twelve fecal filtrates to aggregate Jurkat cells. Twenty  $\mu$ l of each filtrate was added to  $5 \times 10^5$  Jurkat cells in the presence of 10% FCS. The one sample that contained a StcE-reactive species aggregated Jurkat cells to the same extent as 50 ng/ml purified StcE-His; all other samples were negative in this assay, even after 24 hours of incubation (data not shown).

-28-

**StcE contains a zinc metalloprotease active site.**

[0086] As the predicted StcE amino acid sequence has a consensus  $\text{Zn}^{2+}$ -ligand binding site of metalloproteases (434: HEVGHNYGLGH) (SEQ ID NO:3), we examined the possibility that the glutamic acid residue at position 435 is critical for the proteolysis of C1-INH. This amino acid in other zinc metalloproteases acts as the catalytic residue for proteolysis (15) (16), and other researchers have shown that a conservative amino acid substitution from glutamic to aspartic acid disrupts the activity of the protease while maintaining its structure (15). By introducing a single change in the sequence of *stcE* at base 1442 from an A to a T, we created the same mutation and examined the ability of the recombinant mutant (StcE E435D-His) to digest C1-INH. While StcE-His is able to degrade C1-INH, we observed no such cleavage with the mutant protein (Figure 8A) under the same conditions. Indeed, StcE E435D-His was unable even to bind to C1-INH or a similarly sized protein in human serum as determined by Far Western analysis (Figure 8B), suggesting that glutamic acid 435 is necessary for both binding and cleavage of C1-INH. The StcE-mediated aggregation of Jurkat cells was also affected by the E435D mutation. Jurkat cells will aggregate in response to StcE-His at concentrations as low as 1 ng/ml, while cells treated with as much as 200 ng/ml StcE E435D-His did not aggregate (data not shown). Thus, the glutamic acid residue at position 435 is critical for StcE-mediated aggregation of Jurkat cells, as well as proteolysis of and binding to C1-INH.

**Detection of *stcE* among diarrheagenic *E. coli* strains.**

[0087] In order to establish the prevalence of *stcE* among other pathogenic strains of *E. coli*, we examined the Diarrheagenic *E. coli* (DEC) collection, a reference set of 78 *E. coli* strains provided by Dr. Tom Whittam of the University of Pennsylvania, for the presence of *stcE*. This collection contains a variety of enterohemorrhagic, enteropathogenic, and enterotoxigenic *E. coli* strains of different serotypes isolated from humans, non-human primates, and other mammals that are associated with disease symptoms, including diarrhea, hemorrhagic colitis, or HUS. The DEC collection is divided into 15 subgroups based on electrophoretic type, which is indicative of the genetic similarity of one strain to another. By using colony blot analysis, we found that all O157:H7 strains of *E. coli* (DEC3 and DEC4) contain DNA that hybridizes with an

internal one kb region of *stcE* (Table 3). Surprisingly, three of five enteropathogenic O55:H7 strains of *E. coli* (DEC5A, C, & E) also hybridized with the *stcE* probe. Because O157:H7 strains are thought to have evolved from an O55:H7 predecessor, this result suggests a source of the *stcE* gene for current O157:H7 strains of *E. coli*. None of the other strains in the DEC collection hybridized with the *stcE* probe by colony blot analysis.

[0088] To confirm the presence of the gene among the *stcE*-positive groups in the DEC collection, we isolated genomic DNA from DEC3A-E, DEC4A-E, DEC5A-E, EDL933, and EDL933cu and used oligonucleotide pairs designed to amplify regions of *stcE* by PCR. Three primer sets were chosen to amplify *stcE* and its promoter from bases 1-845, 846-1773, and 1774-2798. An appropriately-sized PCR product was amplified with all three primer pairs from EDL933, DEC3A-E, and DEC4A-E (Figure 9). Appropriately sized products were obtained with primer pairs 846-1773 and 1774-2798 for DEC5 A, C, and E, but there were no products with primer pair 1-845 from these strains. It is possible that this region of *stcE*, which includes the putative promoter, is sufficiently different from *stcE* found on pO157 to prevent priming and amplification. DEC5B and D were negative for all three reactions.

Table 3. Incidence of *stcE* and its product in the DEC collection

DEC Number	Predominant Serotype	Disease Category	Number of <i>stcE</i> positive	Number of StcE positive
1A-E	O55:H6	EPEC	0/5	ND
2A-E	O55:H6	EPEC	0/5	ND
3A	O157:H7	EHEC	+	+
3B	O157:H7	EHEC	+	+
3C	O157:H7	EHEC	+	+
3D	O157:H7	EHEC	+	+
3E	O157:H7	EHEC	+	+
4A	O157:H7	EHEC	+	+
4B	O157:H7	EHEC	+	+
4C	O157:H7	EHEC	+	+
4D	O157:H7	EHEC	+	+
4E	O157:H7	EHEC	+	+
5A	O55:H7	EPEC	+	+
5B	O55:H7	EPEC	-	-
5C	O55:H7	EPEC	+	-
5D	O55:H7	EPEC	-	-
5E	O55:H7	EPEC	+	+
6A-E	O111:H12	EPEC	0/5	ND
7A-E	O157:H43	ETEC	0/5	0/5
8A-E	O111:H8	EHEC	0/5	ND
9A-E	O26:H11	EHEC	0/5	ND
10A-E	O26:H11	EHEC	0/5	ND
11A-E	O128:H2	EPEC	0/5	ND
12A-E	O111:H2	EPEC	0/5	ND
13A-E	O128:H7	ETEC	0/5	ND
14A-E	O128:H21	EPEC	0/5	ND
15A-E	O111:H21	EPEC	0/5	ND

Using a one kb probe internal to *stcE*, colony blot analyses were performed to determine which strains in the DEC collection contained *stcE*. Strains that were positive for the gene were checked for secretion of StcE as well proteolytic activity against C1-INH. Strains in bold contained the gene and produced the protein. Strains in italics contained the gene but lacked detectable protein. All other strains in the DEC collection were negative for *stcE*. ND = not done.

[0089] Because previous experiments showed that StcE is released into the culture medium by EDL933 (Figure 3), we examined whether the *stcE*-positive strains from the DEC collection also release StcE into the culture medium. We grew DEC3A-E, DEC4A-E, DEC5A-E, EDL933, and EDL933cu overnight in Lennox L broth at 37°C, harvested and concentrated the culture supernatants 100-fold. By immunoblot analysis we were able to detect StcE-reactive antigen in the supernatants of all *stcE*-positive

-31-

strains and DEC5C (Figure 10). The intensity of the reactive band varied from strain to strain and seemed to be stronger in the DEC3 group. To test if the bacterial-conditioned culture supernatants contained C1-INH proteolytic activity, we mixed purified C1-INH with the supernatants overnight and examined substrate cleavage by immunoblot.

Again, all *stcE*-positive strains except DEC5C were able to degrade C1-INH (Figure 11). Interestingly, DEC5B converted C1-INH from a single band to a doublet; this is unlikely to be related to StcE activity and the significance of this is unknown. It appears that DEC5C is unable to release StcE into the culture medium, although it contains *stcE*-like DNA. This may be due to a lack of expression of the gene or release of the protein from the cell.



1. Perna, N. T., Plunkett III, G., Burland, V., Mau, B., Glasner, J. D., Rose, D. J., Kirkpatrick, H. A., Postal, G., Hackett, J., Klink, S., Boutin, A., Shao, Y., Miller, L., Grotbeck, E. J., Davis, N. W., Lim, A., Dimalanta, E. T., Potamouisis, K. D., Apodaca, J., Anantharaman, T. S., Lin, J., Yen, G., Schwartz, D. C., Welch, R. A. & Blattner, F. R. (2001) *Nature* **409**, 529-533.
2. Waytes, A. T., Rosen, F. S. & Frank, M. M. (1996) *N. Engl. J. Med.* **334**, 1630-1634.
3. Caliezi, C., Willemin, W. A., Zeerleder, S., Redondo, M., Eisele, B. & Hack, C. E. (2000) *Pharmacol. Rev.* **52**, 91-112.
4. Poulle, M., Burnouf-Radosevich, M. & Burnouf, T. (1994) *Blood Coagulation & Fibrinolysis* **5**, 543-9.
5. Kuno, K., Terashima, Y. & Matsushima, K. (1999) *Journal of Biological Chemistry* **274**, 18821-6.
6. Gadek, J. E., Hosea, S. W., Gelfand, J. A., Santaella, M., Wickerhauser, M., Triantaphyllopoulos, D. C. & Frank, M. M. (1980) *N. Engl. J. Med.* **302**, 542-546.
7. Lorenzo, V. D. & Timmis, K. N. (1994) in *Bacterial Pathogenesis*, eds. Clark, V. L. & Bavoil, P. M. (Academic Press, San Diego), Vol. 235, pp. 386-405.
8. O'Farrell, P. H. (1975) *J Biol Chem* **250**, 4007-21.
9. Bauer, M. E. & Welch, R. A. (1996) *Infect. Immun.* **64**, 167-175.
10. Burland, V., Shao, Y., Perna, N. T., Plunkett, G., Sofia, H. J. & Blattner, F. R. (1998) *Nucleic Acids Research* **26**, 4196-4204.
11. Roesch, P. L. & Blomfield, I. C. (1998) *Molecular Microbiology* **27**, 751-61.
12. Catanese, J. & Kress, L. F. (1984) *Biochim. Biophys. Acta* **789**, 37-43.
13. Karmali, M. A., Petric, M., Steele, B. T. & Lim, C. (1983) *Lancet* **1**, 619-620.
14. Caprioli, A., Luzzi, I., Gianviti, A., Russmann, H. & Karch, H. (1995) *J. Med. Microbiol.* **43**, 348-353.
15. Jiang, W. & Bond, J. S. (1992) *FEBS Lett* **312**, 110-114.
16. Jung, C.-M., Matsushita, O., Katayama, S., Minami, J., Sakurai, J. & Okabe, A. (1999) *J. Bact.* **181**, 2816-2822.

-33-

## CLAIMS

What is claimed is:

1. An isolated polypeptide comprising the amino acid sequence of amino acid residues 230-630 of SEQ ID NO:2.
2. The polypeptide of claim 1, wherein the polypeptide comprises amino acid residues 85-734 of SEQ ID NO:2.
3. The polypeptide of claim 1, wherein the polypeptide comprises amino acid residues 24-886 of SEQ ID NO:2.
4. The polypeptide of claim 1, wherein the polypeptide has the ability to bind to and cleave C1 esterase inhibitor.
5. An isolated polypeptide comprising an amino acid sequence having at least 70% amino acid identity to amino acid residues 24-886 of SEQ ID NO:2, the polypeptide comprising a sequence corresponding with and identical to amino acids 434-444 of SEQ ID NO:2, the polypeptide having the ability to bind to and cleave C1 esterase inhibitor.
6. An isolated polypeptide, the amino acid sequence of which comprises at least 17 consecutive amino acid residues of SEQ ID NO:2.
7. The polypeptide of claim 6, wherein the amino acid sequence comprises at least 25 consecutive amino acid residues of SEQ ID NO:2.
8. The polypeptide of claim 6, wherein the amino acid sequence comprises at least 40 consecutive amino acid residues of SEQ ID NO:2.
9. The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 430-446 of SEQ ID NO:2.

-34-

10. The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 421-446 of SEQ ID NO:2.
11. The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 408-448 of SEQ ID NO:2.
12. A genetic construct comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of amino acid residues 24-886 of SEQ ID NO:2 or a sequence complementary thereto, the polynucleotide operably linked to an expression control sequence.
13. The genetic construct of claim 7, wherein the polynucleotide comprises bases 207 through 2795 of SEQ ID NO:1.
14. A cell comprising the construct of claim 12.
15. An antibody that binds specifically to an antigenic determinant found on a polypeptide comprising an amino acid sequence comprising SEQ ID NO:2.
16. The antibody of claim 12, wherein the antibody selectively binds to an epitope in the C1 esterase inhibitor binding domain of the polypeptide.
17. A method of preventing or treating colitis or hemolytic uremic syndrome in a subject infected with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence having substantial sequence identity with amino acid residues 24-886 of SEQ ID NO:2, the inhibitor protein being capable of reducing the activity of C1 esterase inhibitor, comprising the step of:  
administering to the subject an agent selected from the group consisting of an antibody capable of binding to an antigenic determinant of SEQ ID NO:2 and a chelator capable of binding divalent cations in an amount effective to reduce proteolytic inactivation of C1 esterase inhibitor by the inhibitor protein.

18. A method of preventing colitis or hemolytic uremic syndrome in a subject at risk for infection with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence substantially homologous to SEQ ID NO:2, the inhibitor protein being capable of reducing the activity of C1 esterase inhibitor, comprising the step of:

administering to the subject an inactivated polypeptide comprising at least one antigenic determinant of a polypeptide comprising SEQ ID NO:2.

19. A method of preventing or treating colitis and/or hemolytic uremic syndrome in a subject infected with an enterohemorrhagic pathogen expressing an inhibitor protein comprising an amino acid sequence substantially homologous to SEQ ID NO:2, the protein inhibitor being capable of reducing the activity of C1 esterase inhibitor, comprising the step of:

administering to the subject C1 esterase inhibitor in an amount effective to reduce activation of at least one proteolytic cascade selected from the group consisting of classical complement cascade, intrinsic coagulation pathway, and kinin-forming system.

20. A method for testing a molecule for the ability to reduce proteolysis of C1 esterase inhibitor by an inhibitor protein comprising an amino acid sequence substantially homologous to amino acid residues 24 to 886 of SEQ ID NO:2, the inhibitor protein being capable of proteolyzing C1 esterase inhibitor, comprising the steps of:

(a) combining the inhibitor protein, test molecule, and C1 esterase inhibitor under suitable conditions for a period of time sufficient to allow inhibitor protein-C1 esterase inhibitor interaction; and


(b) comparing the level of the C1 esterase inhibitor or C1 esterase inhibitor activity in the mixture of step (a) to that of a control lacking the test molecule.

-36-

21. A method of detecting a bacterium comprising a polynucleotide coding sequence encoding a polypeptide, the polypeptide comprising substantial amino acid identity to residues 24-886 of SEQ ID NO:2, comprising the steps of:

- (a) contacting genomic DNA from the organism with at least one primer pair, each primer pair comprises a first primer and a second primer not complementary to the first primer, wherein the first primer hybridizes to a first portion of the polynucleotide coding sequence, and wherein the second primer hybridizes to a polynucleotide complementary to the polynucleotide coding sequence;
- (b) enzymatically extending the hybridized primers of step (a); and
- (c) detecting the extension products of step (b).


1/11



Lysates of *E. coli* strains containing pO157 induce the aggregation of Jurkat cells, while non-pO157-containing *E. coli* lysates do not aggregate the same cells.

**FIG. 1**


2/11



Purification of StcE-His from WAM2572

FIG. 2

3/11




StcE is produced by strains of *E. coli* that carry pO157 but not in strains that lack pO157 or have a transposon insertion in *stcE*.

FIG. 3



4/11



StcE – His interacts with a human serum protein(s) of approximately 105 kDa.

FIG. 4

5/11





Figure 5. StcE-His cleaves C1 inhibitor in human serum.

FIG. 5


6/11



Differential digestion patterns of C1-INH by StcE-His and *P. aeruginosa* elastase.


FIG. 6

7/11



Detection of StcE in fecal filtrates from children with diarrhea.

FIG. 7



StcE E435D-His lacks proteolytic activity against and the ability to bind to C1-INH.

FIGS. 8A AND 8B

9/11





Figure 9. PCR analysis of *stcE* in the DEC collection.

FIG. 9


10/11



Detection of StcE in bacterial-conditioned culture supernatants.

FIG. 10

11/11



Detection of C1-INH proteolytic activity in bacterial-conditioned culture supernatants.

FIG. 11



## SEQUENCE LISTING

<110> WISCONSIN ALUMNI RESEARCH FOUNDATION

<120> E. COLI O157:H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN AND METHODS OF USE

<130> 096429-9116

<140> Unknown

<141> 2001-10-26

<150> 60/243,675

<151> 2000-10-26

<160> 17

<170> PatentIn version 3.1

<210> 1

<211> 2798

<212> DNA

<213> Unknown Organism

<220>

<221> CDS

<222> (138)..(2798)

<223> Description of Unknown Organism: E. coli O157:H7 plasmid pO157

<400> 1

tttacgaaac aggtgtaa atgtttataaa aataaccaac gactagtga taagtcgctc 60

ctgaaaaaat aaaatataga aatactgtta tatccggctg catgaacact aaaatgaatg 120

agagatggag aacaccg atg aaa tta aag tat ctg tca tgt acg atc ctt 170

Met Lys Leu Lys Tyr Leu Ser Cys Thr Ile Leu

1 5 10

gcc cct ctg gcg att ggg gta ttt tct gca aca gct gct gat aat aat 218

Ala Pro Leu Ala Ile Gly Val Phe Ser Ala Thr Ala Ala Asp Asn Asn

15 20 25

tca gcc att tat ttc aat acc tcc cag cct ata aat gat ctg cag ggt 266

Ser Ala Ile Tyr Phe Asn Thr Ser Gln Pro Ile Asn Asp Leu Gln Gly

30 35 40

tgc ttg gcc gca gag gtg aaa ttt gca caa agc cag att tta ccc gcc 314

Ser Leu Ala Ala Glu Val Lys Phe Ala Gln Ser Gln Ile Leu Pro Ala

45 50 55

cat cct aaa gaa ggg gat agt caa cca cat ctg acc agc ctg cgg aaa 362

His Pro Lys Glu Gly Asp Ser Gln Pro His Leu Thr Ser Leu Arg Lys

60 65 70 75

agt ctg ctg ctt gtc cgt ccg gtg aaa gct gat gat aaa aca cct gtt 410

Ser Leu Leu Leu Val Arg Pro Val Lys Ala Asp Asp Lys Thr Pro Val

80 85 90

cag gtg gaa gcc cgc gat gat aat aat aaa att ctc ggt acg tta acc 458

Gln Val Glu Ala Arg Asp Asp Asn Asn Lys Ile Leu Gly Thr Leu Thr

95 100 105

ctt tat cct cct tca tca cta ccg gat aca atc tac cat ctg gat ggt 506

Leu Tyr Pro Pro Ser Ser Leu Pro Asp Thr Ile Tyr His Leu Asp Gly

110 115 120

gtt ccg gaa ggt ggt atc gat ttc aca cct cat aat gga acg aaa aag 554

Val	Pro	Glu	Gly	Gly	Ile	Asp	Phe	Thr	Pro	His	Asn	Gly	Thr	Lys	Lys	
125						130					135					
atc	att	aat	acg	gtg	gct	gaa	gta	aac	aaa	ctc	agt	gat	gcc	agc	ggg	602
Ile	Ile	Asn	Thr	Val	Ala	Glu	Val	Asn	Lys	Leu	Ser	Asp	Ala	Ser	Gly	
140					145				150						155	
agt	tct	att	cat	agc	cat	cta	aca	aat	aat	gca	ctg	gtg	gag	atc	cat	650
Ser	Ser	Ile	His	Ser	His	Leu	Thr	Asn	Asn	Ala	Leu	Val	Glu	Ile	His	
				160				165					170			
act	gca	aat	ggg	cgt	tgg	gta	aga	gac	att	tat	ctg	ccg	cag	gga	ccc	698
Thr	Ala	Asn	Gly	Arg	Trp	Val	Arg	Asp	Ile	Tyr	Leu	Pro	Gln	Gly	Pro	
			175					180					185			
gac	ctt	gaa	ggg	aag	atg	gtt	cgc	ttt	gtt	tcg	tct	gca	ggc	tat	agt	746
Asp	Leu	Glu	Gly	Lys	Met	Val	Arg	Phe	Val	Ser	Ser	Ala	Gly	Tyr	Ser	
		190					195					200				
tca	acg	gtt	ttt	tat	ggg	gat	cga	aaa	gtc	aca	ctc	tcg	gtg	ggg	aac	794
Ser	Thr	Val	Phe	Tyr	Gly	Asp	Arg	Lys	Val	Thr	Leu	Ser	Val	Gly	Asn	
		205				210					215					
act	ctt	ctg	ttc	aaa	tat	gta	aat	ggg	cag	tgg	ttc	cgc	tcc	ggg	gaa	842
Thr	Leu	Leu	Phe	Lys	Tyr	Val	Asn	Gly	Gln	Trp	Phe	Arg	Ser	Gly	Glu	
		220			225				230						235	
ctg	gag	aat	aat	cga	atc	act	tat	gct	cag	cat	att	tgg	agt	gct	gaa	890
Leu	Glu	Asn	Asn	Arg	Ile	Thr	Tyr	Ala	Gln	His	Ile	Trp	Ser	Ala	Glu	
				240				245						250		
ctg	cct	gcg	cac	tgg	atc	gtg	cct	ggg	tta	aac	ttg	gtg	att	aaa	cag	938
Leu	Pro	Ala	His	Trp	Ile	Val	Pro	Gly	Leu	Asn	Leu	Val	Ile	Lys	Gln	
			255				260						265			
ggc	aat	ctg	agc	ggg	cgc	cta	aat	gat	atc	aag	att	gga	gca	ccg	ggg	986
Gly	Asn	Leu	Ser	Gly	Arg	Leu	Asn	Asp	Ile	Lys	Ile	Gly	Ala	Pro	Gly	
		270					275					280				
gag	ctg	ttg	ttg	cat	aca	att	gat	atc	ggg	atg	ttg	acc	act	ccc	cgg	1034
Glu	Leu	Leu	Leu	His	Thr	Ile	Asp	Ile	Gly	Met	Leu	Thr	Thr	Pro	Arg	
		285				290					295					
gat	cgc	ttt	gat	ttt	gcc	aaa	gac	aaa	gaa	gca	cat	agg	gaa	tat	ttc	1082
Asp	Arg	Phe	Asp	Phe	Ala	Lys	Asp	Lys	Glu	Ala	His	Arg	Glu	Tyr	Phe	
		300			305				310						315	
cag	acc	att	cct	gta	agt	cgt	atg	att	gtt	aat	aat	tat	gcg	cct	cta	1130
Gln	Thr	Ile	Pro	Val	Ser	Arg	Met	Ile	Val	Asn	Asn	Tyr	Ala	Pro	Leu	
				320				325						330		
cac	cta	aag	gaa	gtt	atg	tta	cca	acc	gga	gag	tta	ttg	aca	gat	atg	1178
His	Leu	Lys	Glu	Val	Met	Leu	Pro	Thr	Gly	Glu	Leu	Leu	Thr	Asp	Met	
			335					340					345			
gat	cca	gga	aat	ggg	ggg	tgg	cat	agt	ggg	aca	atg	cgt	caa	aga	ata	1226
Asp	Pro	Gly	Asn	Gly	Gly	Trp	His	Ser	Gly	Thr	Met	Arg	Gln	Arg	Ile	
		350					355					360				
ggg	aaa	gaa	ttg	gtt	tcg	cat	ggc	att	gat	aat	gct	aac	tat	ggg	tta	1274
Gly	Lys	Glu	Leu	Val	Ser	His	Gly	Ile	Asp	Asn	Ala	Asn	Tyr	Gly	Leu	
		365				370					375					
aat	agt	acc	gca	ggc	tta	ggg	gag	aat	agt	cat	cca	tat	gta	gtt	gcg	1322
Asn	Ser	Thr	Ala	Gly	Leu	Gly	Glu	Asn	Ser	His	Pro	Tyr	Val	Val	Ala	
					385					390					395	

caa tta gcg gca cat aat agc cgc ggt aat tat gct aat ggc atc cag Gln Leu Ala Ala His Asn Ser Arg Gly Asn Tyr Ala Asn Gly Ile Gln 400 405 410	1370
gtt cat ggt ggc tcc gga ggt ggg gga att gtt act tta gat tcc aca Val His Gly Gly Ser Gly Gly Gly Gly Ile Val Thr Leu Asp Ser Thr 415 420 425	1418
ttg ggg aat gag ttc agt cat gaa gtt ggt cat aat tat ggt ctt ggt Leu Gly Asn Glu Phe Ser His Glu Val Gly His Asn Tyr Gly Leu Gly 430 435 440	1466
cat tat gta gat ggt ttc aag ggt tct gta cat cgt agt gca gaa aat His Tyr Val Asp Gly Phe Lys Gly Ser Val His Arg Ser Ala Glu Asn 445 450 455	1514
aac aac tca act tgg gga tgg gat ggt gat aaa aaa cgg ttt att cct Asn Asn Ser Thr Trp Gly Trp Asp Gly Asp Lys Lys Arg Phe Ile Pro 460 465 470 475	1562
aac ttt tat ccg tct caa aca aat gaa aag agt tgt ctg aat aat cag Asn Phe Tyr Pro Ser Gln Thr Asn Glu Lys Ser Cys Leu Asn Asn Gln 480 485 490	1610
tgt caa gaa ccg ttt gat gga cac aaa ttt ggt ttt gac gcc atg gcg Cys Gln Glu Pro Phe Asp Gly His Lys Phe Gly Phe Asp Ala Met Ala 495 500 505	1658
gga ggc agc cct ttc tct gct gca aac cgt ttc aca atg tat act ccg Gly Gly Ser Pro Phe Ser Ala Ala Asn Arg Phe Thr Met Tyr Thr Pro 510 515 520	1706
aat tca tcg gct atc atc cag cgt ttt ttt gaa aat aaa gct gtg ttc Asn Ser Ser Ala Ile Ile Gln Arg Phe Phe Glu Asn Lys Ala Val Phe 525 530 535	1754
gat agc cgt tcc tcc acc ggc ttc agc aag tgg aat gca gat acg cag Asp Ser Arg Ser Ser Thr Gly Phe Ser Lys Trp Asn Ala Asp Thr Gln 540 545 550 555	1802
gaa atg gaa ccg tat gaa cac acc att gac cgt gcg gag cag att acg Glu Met Glu Pro Tyr Glu His Thr Ile Asp Arg Ala Glu Gln Ile Thr 560 565 570	1850
gct tca gtc aat gag cta agt gaa agc aaa atg gct gag ctg atg gca Ala Ser Val Asn Glu Leu Ser Glu Ser Lys Met Ala Glu Leu Met Ala 575 580 585	1898
gag tac gct gtc gtc aaa gtg cat atg tgg aac ggt aac tgg aca aga Glu Tyr Ala Val Val Lys Val His Met Trp Asn Gly Asn Trp Thr Arg 590 595 600	1946
aac atc tat atc cct aca gcc tcc gca gat aat aga ggc agt atc ctg Asn Ile Tyr Ile Pro Thr Ala Ser Ala Asp Asn Arg Gly Ser Ile Leu 605 610 615	1994
acc atc aac cat gag gcc ggt tat aat agt tat ctg ttt ata aat ggt Thr Ile Asn His Glu Ala Gly Tyr Asn Ser Tyr Leu Phe Ile Asn Gly 620 625 630 635	2042
gac gaa aag gtc gtt tcc cag ggg tat aaa aag agc ttt gtt tcc gat Asp Glu Lys Val Val Ser Gln Gly Tyr Lys Lys Ser Phe Val Ser Asp 640 645 650	2090
ggt cag ttc tgg aaa gaa cgt gat gtg gtt gat act cgt gaa gcg cgt Gly Gln Phe Trp Lys Glu Arg Asp Val Val Asp Thr Arg Glu Ala Arg 655 660 665	2138

aag cca gag cag ttt ggt gtt cct gtg acg acc ctg gtg ggg tat tac 2186  
 Lys Pro Glu Gln Phe Gly Val Pro Val Thr Thr Leu Val Gly Tyr Tyr  
 670 675 680

gat ccg gaa ggc acg ctg tca agc tac atc tat cct gcg atg tat ggt 2234  
 Asp Pro Glu Gly Thr Leu Ser Ser Tyr Ile Tyr Pro Ala Met Tyr Gly  
 685 690 695

gcc tat ggc ttc act tat tcc gat gat agt cag aat cta tcc gat aac 2282  
 Ala Tyr Gly Phe Thr Tyr Ser Asp Asp Ser Gln Asn Leu Ser Asp Asn  
 700 705 710 715

gac tgc cag ctg cag gtg gat acg aaa gaa ggg cag ttg cga ttc aga 2330  
 Asp Cys Gln Leu Gln Val Asp Thr Lys Glu Gly Gln Leu Arg Phe Arg  
 720 725 730

ctg gct aat cac cgg gct aac aac act gta atg aat aag ttc cat att 2378  
 Leu Ala Asn His Arg Ala Asn Asn Thr Val Met Asn Lys Phe His Ile  
 735 740 745

aac gtg cca aca gaa agt cag ccc aca cag gcc aca ttg gtt tgc aat 2426  
 Asn Val Pro Thr Glu Ser Gln Pro Thr Gln Ala Thr Leu Val Cys Asn  
 750 755 760

aac aag ata ctg gat acc aaa tcg ctc aca cct gcg cca gaa gga ctt 2474  
 Asn Lys Ile Leu Asp Thr Lys Ser Leu Thr Pro Ala Pro Glu Gly Leu  
 765 770 775

acc tat act gta aat ggg cag gca ctt cca gca aaa gaa aac gag gga 2522  
 Thr Tyr Thr Val Asn Gly Gln Ala Leu Pro Ala Lys Glu Asn Glu Gly  
 780 785 790 795

tgc atc gtg tcc gtg aat tca ggt aaa cgt tac tgt ttg ccg gtt ggt 2570  
 Cys Ile Val Ser Val Asn Ser Gly Lys Arg Tyr Cys Leu Pro Val Gly  
 800 805 810

caa cgg tca gga tat agc ctt cct gac tgg att gtt ggg cag gaa gtc 2618  
 Gln Arg Ser Gly Tyr Ser Leu Pro Asp Trp Ile Val Gly Gln Glu Val  
 815 820 825

tat gtc gac agc ggg gct aaa gcg aaa gtg ctg ctt tct gac tgg gat 2666  
 Tyr Val Asp Ser Gly Ala Lys Ala Lys Val Leu Leu Ser Asp Trp Asp  
 830 835 840

aac ctg tcc tat aac agg att ggt gag ttt gta ggt aat gtg aac cca 2714  
 Asn Leu Ser Tyr Asn Arg Ile Gly Glu Phe Val Gly Asn Val Asn Pro  
 845 850 855

gct gat atg aaa aaa gtt aaa gcc tgg aac gga cag tat ttg gac ttc 2762  
 Ala Asp Met Lys Lys Val Lys Ala Trp Asn Gly Gln Tyr Leu Asp Phe  
 860 865 870 875

agt aaa cct agg tca atg agg gtt gta tat aaa taa 2798  
 Ser Lys Pro Arg Ser Met Arg Val Val Tyr Lys  
 880 885

<210> 2  
 <211> 886  
 <212> PRT  
 <213> Unknown Organism

<400> 2

Met Lys Leu Lys Tyr Leu Ser Cys Thr Ile Leu Ala Pro Leu Ala Ile  
 1 5 10 15

Gly Val Phe Ser Ala Thr Ala Ala Asp Asn Asn Ser Ala Ile Tyr Phe  
                   20                                  25                                  30

Asn Thr Ser Gln Pro Ile Asn Asp Leu Gln Gly Ser Leu Ala Ala Glu  
                   35                                  40                                  45

Val Lys Phe Ala Gln Ser Gln Ile Leu Pro Ala His Pro Lys Glu Gly  
                   50                                  55                                  60

Asp Ser Gln Pro His Leu Thr Ser Leu Arg Lys Ser Leu Leu Leu Val  
                   65                                  70                                  75                                  80

Arg Pro Val Lys Ala Asp Asp Lys Thr Pro Val Gln Val Glu Ala Arg  
                                   85                                  90                                  95

Asp Asp Asn Asn Lys Ile Leu Gly Thr Leu Thr Leu Tyr Pro Pro Ser  
                                   100                                  105                                  110

Ser Leu Pro Asp Thr Ile Tyr His Leu Asp Gly Val Pro Glu Gly Gly  
                   115                                  120                                  125

Ile Asp Phe Thr Pro His Asn Gly Thr Lys Lys Ile Ile Asn Thr Val  
                   130                                  135                                  140

Ala Glu Val Asn Lys Leu Ser Asp Ala Ser Gly Ser Ser Ile His Ser  
                   145                                  150                                  155                                  160

His Leu Thr Asn Asn Ala Leu Val Glu Ile His Thr Ala Asn Gly Arg  
                                   165                                  170                                  175

Trp Val Arg Asp Ile Tyr Leu Pro Gln Gly Pro Asp Leu Glu Gly Lys  
                   180                                  185                                  190

Met Val Arg Phe Val Ser Ser Ala Gly Tyr Ser Ser Thr Val Phe Tyr  
                   195                                  200                                  205

Gly Asp Arg Lys Val Thr Leu Ser Val Gly Asn Thr Leu Leu Phe Lys  
                   210                                  215                                  220

Tyr Val Asn Gly Gln Trp Phe Arg Ser Gly Glu Leu Glu Asn Asn Arg  
                   225                                  230                                  235                                  240

Ile Thr Tyr Ala Gln His Ile Trp Ser Ala Glu Leu Pro Ala His Trp  
                                   245                                  250                                  255

Ile Val Pro Gly Leu Asn Leu Val Ile Lys Gln Gly Asn Leu Ser Gly  
                   260                                  265                                  270

Arg Leu Asn Asp Ile Lys Ile Gly Ala Pro Gly Glu Leu Leu Leu His

275	280	285
Thr Ile Asp Ile Gly Met Leu Thr Thr Pro Arg Asp Arg Phe Asp Phe 290 295 300		
Ala Lys Asp Lys Glu Ala His Arg Glu Tyr Phe Gln Thr Ile Pro Val 305 310 315 320		
Ser Arg Met Ile Val Asn Asn Tyr Ala Pro Leu His Leu Lys Glu Val 325 330 335		
Met Leu Pro Thr Gly Glu Leu Leu Thr Asp Met Asp Pro Gly Asn Gly 340 345 350		
Gly Trp His Ser Gly Thr Met Arg Gln Arg Ile Gly Lys Glu Leu Val 355 360 365		
Ser His Gly Ile Asp Asn Ala Asn Tyr Gly Leu Asn Ser Thr Ala Gly 370 375 380		
Leu Gly Glu Asn Ser His Pro Tyr Val Val Ala Gln Leu Ala Ala His 385 390 395 400		
Asn Ser Arg Gly Asn Tyr Ala Asn Gly Ile Gln Val His Gly Gly Ser 405 410 415		
Gly Gly Gly Gly Ile Val Thr Leu Asp Ser Thr Leu Gly Asn Glu Phe 420 425 430		
Ser His Glu Val Gly His Asn Tyr Gly Leu Gly His Tyr Val Asp Gly 435 440 445		
Phe Lys Gly Ser Val His Arg Ser Ala Glu Asn Asn Asn Ser Thr Trp 450 455 460		
Gly Trp Asp Gly Asp Lys Lys Arg Phe Ile Pro Asn Phe Tyr Pro Ser 465 470 475 480		
Gln Thr Asn Glu Lys Ser Cys Leu Asn Asn Gln Cys Gln Glu Pro Phe 485 490 495		
Asp Gly His Lys Phe Gly Phe Asp Ala Met Ala Gly Gly Ser Pro Phe 500 505 510		
Ser Ala Ala Asn Arg Phe Thr Met Tyr Thr Pro Asn Ser Ser Ala Ile 515 520 525		
Ile Gln Arg Phe Phe Glu Asn Lys Ala Val Phe Asp Ser Arg Ser Ser 530 535 540		

Thr Gly Phe Ser Lys Trp Asn Ala Asp Thr Gln Glu Met Glu Pro Tyr  
 545 550 555 560  
 Glu His Thr Ile Asp Arg Ala Glu Gln Ile Thr Ala Ser Val Asn Glu  
 565 570 575  
 Leu Ser Glu Ser Lys Met Ala Glu Leu Met Ala Glu Tyr Ala Val Val  
 580 585 590  
 Lys Val His Met Trp Asn Gly Asn Trp Thr Arg Asn Ile Tyr Ile Pro  
 595 600 605  
 Thr Ala Ser Ala Asp Asn Arg Gly Ser Ile Leu Thr Ile Asn His Glu  
 610 615 620  
 Ala Gly Tyr Asn Ser Tyr Leu Phe Ile Asn Gly Asp Glu Lys Val Val  
 625 630 635 640  
 Ser Gln Gly Tyr Lys Lys Ser Phe Val Ser Asp Gly Gln Phe Trp Lys  
 645 650 655  
 Glu Arg Asp Val Val Asp Thr Arg Glu Ala Arg Lys Pro Glu Gln Phe  
 660 665 670  
 Gly Val Pro Val Thr Thr Leu Val Gly Tyr Tyr Asp Pro Glu Gly Thr  
 675 680 685  
 Leu Ser Ser Tyr Ile Tyr Pro Ala Met Tyr Gly Ala Tyr Gly Phe Thr  
 690 695 700  
 Tyr Ser Asp Asp Ser Gln Asn Leu Ser Asp Asn Asp Cys Gln Leu Gln  
 705 710 715 720  
 Val Asp Thr Lys Glu Gly Gln Leu Arg Phe Arg Leu Ala Asn His Arg  
 725 730 735  
 Ala Asn Asn Thr Val Met Asn Lys Phe His Ile Asn Val Pro Thr Glu  
 740 745 750  
 Ser Gln Pro Thr Gln Ala Thr Leu Val Cys Asn Asn Lys Ile Leu Asp  
 755 760 765  
 Thr Lys Ser Leu Thr Pro Ala Pro Glu Gly Leu Thr Tyr Thr Val Asn  
 770 775 780  
 Gly Gln Ala Leu Pro Ala Lys Glu Asn Glu Gly Cys Ile Val Ser Val  
 785 790 795 800  
 Asn Ser Gly Lys Arg Tyr Cys Leu Pro Val Gly Gln Arg Ser Gly Tyr  
 805 810 815

Ser Leu Pro Asp Trp Ile Val Gly Gln Glu Val Tyr Val Asp Ser Gly  
820 825 830

Ala Lys Ala Lys Val Leu Leu Ser Asp Trp Asp Asn Leu Ser Tyr Asn  
835 840 845

Arg Ile Gly Glu Phe Val Gly Asn Val Asn Pro Ala Asp Met Lys Lys  
850 855 860

Val Lys Ala Trp Asn Gly Gln Tyr Leu Asp Phe Ser Lys Pro Arg Ser  
865 870 875 880

Met Arg Val Val Tyr Lys  
885

<210> 3  
<211> 11  
<212> PRT  
<213> Unknown Organism

<220>  
<221> misc\_feature  
<223> Description of Unknown Organism: E. coli O157:H7 plasmid pO157

<400> 3

His Glu Val Gly His Asn Tyr Gly Leu Gly His  
1 5 10

<210> 4  
<211> 28  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 4  
ccctcgagtt tacgaaacag gtgtaaat 28

<210> 5  
<211> 30  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 5  
cctctagatt atttatatac aaccctcatt 30

<210> 6  
<211> 30  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 6  
ccgagctccg atgaaattaa agtatctgtc 30

<210> 7  
<211> 27  
<212> DNA



<213> Synthetic Oligonucleotide

<400> 7

cctcgagttt atatacaacc ctcattg

27

<210> 8

<211> 23

<212> DNA

<213> Synthetic Oligonucleotide

<400> 8

ccgctccggt gaactggaga ata

23

<210> 9

<211> 30

<212> DNA

<213> Synthetic Oligonucleotide

<400> 9

gaccataatt' atgaccaaca tcatgactga

30

<210> 10

<211> 23

<212> DNA

<213> Synthetic Oligonucleotide

<400> 10

ccttatctgc ggaggctgta ggg

23

<210> 11

<211> 31

<212> DNA

<213> Synthetic Oligonucleotide

<400> 11

tgagttcagt catgatgttg gtcataatta t

31

<210> 12

<211> 25

<212> DNA

<213> Synthetic Oligonucleotide

<400> 12

gagaataatc gaatcactta tgctc

25

<210> 13

<211> 21

<212> DNA

<213> Synthetic Oligonucleotide

<400> 13

cggtggagga acggctatcg a

21

<210> 14

<211> 30

<212> DNA

<213> Synthetic Oligonucleotide

<400> 14

tttacgaaac aggtgtaaat atgttataaa

30

<210> 15  
<211> 21  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 15  
cagttcaccg gagcggaacc a 21

<210> 16  
<211> 25  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 16  
gcttcagcaa gtggaatgca gatac 25

<210> 17  
<211> 30  
<212> DNA  
<213> Synthetic Oligonucleotide

<400> 17  
ttatttatat acaaccctca ttgacctagg 30

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
**WO 02/034918 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/31,  
15/63, C07K 14/245, 16/12, A61K 39/108, C12Q 1/44,  
1/68, C12N 9/52

(21) International Application Number: PCT/US01/47719

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/243,675 26 October 2000 (26.10.2000) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH  
FOUNDATION [US/US]; P.O. Box 7365, Madison, WI  
53707-7365 (US).

(72) Inventors: WELCH, Rodney, A.; 1825 Van Hise Avenue,  
Madison, WI 53705 (US). LATHEM, Wyndham, W.; 508  
West Wilson, #1, Madison, WI 53703 (US).

(74) Agents: FAHRLANDER, Jill, A. et al.; Michael Best &  
Friedrich, LLP, One South Pinckney Street, Suite 700, P.O.  
Box 1806, Madison, WI 53701-1806 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
30 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/034918 A3

(54) Title: E. COLI 0157:H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN STCE AND USES THEREOF

(57) Abstract: Disclosed is a p0157 plasmid-encoded polypeptide found in *E. coli* EDL933 and other enterohemorrhagic *E. coli* that binds to the cleaves C1-esterase inhibitor (stcE). Also disclosed are methods employing the polypeptide for diagnosing and treating colitis or hemolytic uremic syndrome, and methods of detecting potential therapeutics.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/47719

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C12N15/63 C07K14/245 C07K16/12 A61K39/108  
C12Q1/44 C12Q1/68 C12N9/52

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, WPI Data, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VALERIE BURLAND ET AL.: "The complete DNA sequence and analysis of the large virulence plasmid of Escherichia coli 0157:H7" NUCLEIC ACIDS RESEARCH, vol. 26, no. 18, 1998, pages 4196-4204, XP002169993 abstract page 4200, right-hand column, paragraph 2	1-15,21
X	-& DATABASE EMBL 'Online! Database Entry AF074613, 4 November 1998 (1998-11-04) BURLAND V. ET AL.: "Escherichia coli 0157:H7 plasmid p0157, complete sequence" Database accession no. AF074613 XP002215293 Sequence 23016..25712 --- -/-	1-15,21

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

1 October 2002

Date of mailing of the international search report

18/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/47719

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! Database entry EC33P0157, 30 June 1999 (1999-06-30) BRUNDER W.: "E. coli 3.3 kb DNA fragment from plasmid p0157" Database accession no. Y11831 XP002215291 the whole document</p>	1-15,21
X	<p>DATABASE SWALL 'Online! Entry number Q9ZAL1, 1 May 1999 (1999-05-01) BRUNDER, W.: "Hypothetical 34.0 kDa protein (Fragment)" Database accession no. Q9ZAL1 XP002215292 the whole document</p>	6-8
P,X	<p>W.W. LATHEM ET AL.: "A novel metalloprotease secreted by Escherichia coli O157:H7 cleaves C1 esterase inhibitor, a regulator of multiple proteolytic cascades" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY., vol. 101, 20 - 24 May 2001, page 113 XP002215289 AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US ISSN: 0067-2777 abstract B-324</p>	1-21
P,X	<p>S.E. WITOWSKI ET AL.: "StcE, a novel metalloprotease from enterohemorrhagic Escherichia coli, is specific for p0157-containing strains of diarrheagenic E. coli" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY., vol. 101, 20 - 24 May 2001, page 113 XP002215290 AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US ISSN: 0067-2777 abstract B-321</p>	1-21

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/47719

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 17-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**